Clinical Trial Update: Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia [NA]

View source ↗

Summary

Clinical trial update on alisertib in patients with myelofibrosis or relapsed/refractory acute megakaryoblastic leukemia (AMKL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Megakaryoblastic Leukemia
• Myelofibrosis

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Northwestern University | Conditions: Acute Megakaryoblastic Leukemia, Myelofibrosis | NA | Status: UNKNOWN | Results posted: 2020-12-19